In the News
The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China's hot IPOs
 
Greg Scott joined Foley's Eye on China webinar on life science innovation
>>Foley webinar...
Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

>> Preview...

Unit Sales Down, Revenues Up at China Biologic

publication date: Nov 16, 2007
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
China Biologic Products  reported record financial results for Q3 even though shipments of its blood-based products were lower than the year earlier. The secret? Albumin and other plasma-based products are in short supply in China, forcing China officials to allow prices to climb. In fact, China Biologic said the price of one product skyrocketed 425%. Counterfeiting forced regulators to crack down on all producers, restricting supplies still further.  More details...

Stock Symbol: (OTCBB: CBPO)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events
BioBay Investor Forum 2010
Suzhou, China
November 3 - 4, 2010
China Forum 2010
Munich, Germany
November 14, 2010

 
ChinaBio® Investor Forum 2010 - Guangzhou
Guangzhou, China
December 21, 2010
Partner Events
BioPharm America™ 2010
Boston, MA, USA
September 15–17, 2010

CALAsia 2010
San Diego, USA
October 4-5, 2010

CHINA PRETRIALS 2010: Global Preclinical Development Summit
Beijing, China
October 17-19, 2010

CHINA TRIALS 2010
Beijing, China
November 7-9, 2010

12th Shanghai International Forum on Biotechnology & Pharmaceutical Industry (BIO-FORUM)
Beijing, China
November 9-11, 2010
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners